Mining TCGA and GEO databases for the prediction of poor prognosis in lung adenocarcinoma based on up-regulated expression of TNS4

Feng Liu, MDa,b, Xinliang Gao, MDc, Wei Liu, PhDc, Wujun Xue, PhDa,*

Abstract
To investigate the clinical significance of Tensin4 (TNS4) in human cancers, particularly lung cancer, we mined the Cancer Genome Atlas database for lung adenocarcinoma (TCGA-LUAD) and the Gene Expression Omnibus database to predict poor prognosis based on the up-regulated expression of TNS4 in LUAD. The correlation between the clinical pathologic features of patients and TNS4 gene expression was analyzed using the Wilcoxon signed-rank test. Cox regression analysis was used to evaluate the association of clinicopathologic characteristics with the overall survival (OS) of cancer patients using TCGA data. The relationship between TNS4 expression and cancer patient survival was evaluated with Kaplan–Meier survival curves and meta-analyses. GO and KEGG were also included in the data mining methods. The expression level of TNS4 in LUAD tissue was higher than that in adjacent normal tissue (P < .001). According to the Kaplan–Meier survival curve, LUAD patients with high TNS4 expression had worse prognosis than those with low TNS4 expression (P < .001 for OS; P = .028 for progression-free survival). A positive correlation between TNS4 expression and poor OS was found with both univariate and multivariate analyses. Increased TNS4 expression in LUAD was closely correlated with a higher disease stage (P = .007), positive lymph nodes (P = .005), and larger tumor size (P = .002). Moreover, meta-analysis including seven independent datasets showed LUAD patients with higher TNS4 had poorer OS (combined hazard ratio = 1.27, 95% confidence interval 1.16–1.39). In the high-TNS4 population, regulation of the actin cytoskeleton, extracellular matrix receptor interactions, and focal adhesion were differentially enriched. Integrin α6β4 and laminin-5 genes were also associated with TNS4. TNS4 expression may be a potential biomarker for predicting poor survival in LUAD. Moreover, the correlation between TNS4 and integrin α6β4 may be attributed to the role of TNS4 in LUAD.

Abbreviations: CI = confidence interval, DEGs = differentially expressed genes, ECM = extracellular matrix, FDR = false discovery rate, GO = gene ontology, GSEA = gene set enrichment analysis, HR = hazard ratio, KEGG = Kyoto encyclopedia of genes and genomes, LUAD = lung adenocarcinoma, OS = overall survival, PFS = progression-free survival, TCGA = the Cancer Genome Atlas database, TNS4 = Tensin4.

Keywords: focal adhesion, lung adenocarcinoma, prognosis, TNS4.

1. Introduction
With a 2-year survival rate of 35% to 44% and a 5-year survival rate of 18%, lung cancer is one of the leading causes of cancer-related deaths in humans.[1,2] In 2020, there were 228,820 new diagnoses and 135,720 cancer-related deaths from lung and bronchial cancer in the United States.[3] In recent years, lung adenocarcinoma (LUAD) has become the most prevalent subtype of lung cancer.[4] Many genes have been found to promote the proliferation or inhibit the death of lung cancer cells through various pathways, thereby participating in the occurrence and development of LUAD. Targeting the carcinogenic mechanisms mediated by these genes can provide new directions for LUAD treatment.

TNS4 (tensin-4, also known as Cten) is a protein coding gene belonging to the tensin family. TNS4 is involved in cell migration, carcinoid development, and communication in the cytoskeleton. Studies on the action mechanisms of tensins revealed that the members of this family use their Src Homologous 2 binding domains, thereby regulating various biological processes, including proliferation, apoptosis, differentiation, cell adhesion, migration, and invasion.[5] Over-expression of TNS4 has been detected in human cancers, such as gastric cancer, esophageal cancer, hepatocellular carcinoma, colorectal cancer, breast cancer primary melanoma, and pancreatic...
cancer[12-14] but the protein is down-regulated in prostate cancer.[15] Elevated expression of TNS4 has also been found in lung cancer.[16] Elevated TNS4 expression promotes the tumorigenesis and development of lung cancer via inducing and stabilizing epithelial-mesenchymal transition.[17,18] It has been reported that high expression of TNS4 affects the prognosis of LUAD.[19,20] However, the correlation of TNS4 expression with poor LUAD prognosis is still not fully understood due to a lack of comprehensive analysis using multiple datasets and studies on the potential mechanism underlying the role of TNS4 in the prognosis of LUAD.

To this end, we aimed to evaluate the prognostic significance of TNS4 expression in LUAD by using a bioinformatics approach to analyze the differential expression of TNS4 mRNA using the Cancer Genome Atlas database for lung adenocarcinoma (TCGA-LUAD), with comparisons between LUAD tissues and normal tissues. In addition, to explore the overall prognostic significance of TNS4 in LUAD, a comprehensive meta-analysis was performed using data from the Gene Expression Omnibus (GEO) database. To investigate the potential mechanism underlying the role of TNS4 in the prognosis of LUAD, enrichment analysis was conducted using the gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathways. Our study provides direct evidence for the up-regulation of TNS4 expression as a prognostic biomarker for LUAD patients as well as a potential therapeutic target for LUAD.

2. Material and Methods

2.1. Data mining from public databases

In this study, the RNA data (HTSeq-FPKM) for TCGA-LUAD and related clinical information were mainly obtained from the University of California Santa Cruz Xena website. The LUAD mRNA microarray data and the corresponding clinical data were obtained from the GEO database. The inclusion criteria for these datasets were GEO series (GSE) with more than 100 LUAD cases and GSE with overall survival (OS) and transcriptional data. Lung cancer samples in the TCGA database were included for further survival analysis and to evaluate the clinical relationships in the high and low TNS4 expression groups. Our research is based on open-source data and therefore does not require ethics committee approval for the study.

2.2. Meta-analysis

To evaluate the prognostic significance of TNS4 in LUAD patients, meta-analysis was performed using both TCGA and GEO datasets. To evaluate the correlation of TNS4 expression with the prognosis of LUAD patients, the hazard ratio (HR) and 95% confidence interval (CI) were calculated. To assess the heterogeneity across datasets, the Q test (I2 statistics) was performed. In the event of no obvious heterogeneity (I2 < 50%), a fixed-effects model was selected. Otherwise, a random-effects model was applied. The R software package “meta” was used for meta-analysis.

2.3. Enrichment analysis

In the TCGA-LUAD cohort, differentially expressed genes (DEGs) were identified by comparing the patients in the high-risk and low-risk groups using the “limma” package in R software. For the candidate genes, that is, DEGs with log2 fold change ≥1, GO enrichment analysis was performed using the “ClusterProfiler” package in R software, with a false discovery rate (FDR) < 0.05. Gene set enrichment analysis (GSEA) of the DEGs was also carried out for gene candidates that met the requirements (log2 fold change ≥1 and FDR < 0.05 in the KEGG pathway analysis). The correlation between TNS4 expression and gene expression in the focal adhesion pathway was also investigated.

2.4. Statistical analysis

In this study, R software (v.3.6.2) was used for statistical analysis of all data. The differential expression of TNS4 between tumor and normal samples was determined with the Wilcoxon test. The median TNS4 expression level was set as the cutoff value. The OS and progression-free survival (PFS) curves for the high and low TNS4 expression groups were established with Kaplan–Meier survival analysis. The degree of the impact of TNS4 expression on survival and other clinical characteristics (gender, age, history of smoking, stage, tumor size, and lymph node status) was determined with univariate and multivariate Cox analyses. The relationship between the clinical pathologic features of the patient and TNS4 expression was assessed using the Wilcoxon test (for two groups) or the Kruskal–Wallis test (for more than two groups) and logistic regression. P values < .05 on both sides were considered statistically significant.

3. Results

3.1. OS and PFS prognostic analysis of TCGA-LUAD data

TCGA-LUAD contains RNA sequencing data for 535 tumor tissues (including two recurrent tumor samples) and 59 normal tissues collected from 513 patients up to March 2021. After merging the clinical data, 500 cases in the TCGA-LUAD database with RNA sequencing, OS, and clinical data were used for OS prognostic and relationship analyses (Table 1). Five hundred and four cases with PFS data were used for PFS prognostic analysis. The level of TNS4 expression in all tumor tissues was higher than that in normal tissues (Fig. 1a,b). According to the Kaplan–Meier survival curves, the OS and PFS of LUAD patients with over-expressed TNS4 were worse than those in LUAD patients with low TNS4 expression (Fig. 1c,d, P < .05). Data for 469 LUAD samples with TNS4 expression information across all patient characteristics were used to predict survival-time (time-to-event) outcomes with one (univariate) or more (multivariate) predictors using Cox’s proportional hazards model. As shown

| Table 1 | TCGA lung adenocarcinoma patient characteristics. |
|---------|--------------------------------------------------|
| Clinical characteristics | Average (range) or n (%) |
| Age (yr) | 65.3 (33–88) |
| Gender | | |
| Male | 230 (46.0%) |
| Female | 270 (54.0%) |
| History of smoking | | |
| Smoker | 415 (85.4%) |
| Nonsmoker | 71 (14.6%) |
| Stage | | |
| Stage I | 268 (54.5%) |
| Stage II | 119 (24.2%) |
| Stage III | 80 (16.3%) |
| Stage IV | 25 (5.1%) |
| T factor | 497 |
| T1 | 167 (33.6%) |
| T2 | 268 (53.9%) |
| T3 | 45 (9.1%) |
| T4 | 18 (3.6%) |
| Lymph node status | 489 |
| N0 | 324 (66.3%) |
| N1 | 94 (19.2%) |
| N2 | 69 (14.1%) |
| N3 | 2 (0.4%) |
in Figure 1e, univariate Cox regression analysis indicated that TNS4 overexpression was significantly correlated with poor OS (HR was 1.21 and 95%CI was 1.11–1.31; \( P < .05 \)). In addition, TNS4 expression was independently associated with OS in multivariate Cox analysis (HR was 1.18 and 95%CI was 1.08–1.28, \( P < .05 \)).

### 3.2. Correlation of TNS4 expression with clinical characteristics in LUAD patients

Although TNS4 expression had no correlation with age, gender, and smoking history (Fig. 2a–c), however, data analysis showed that up-regulated TNS4 expression was significantly correlated

---

**Figure 1.** The TNS4 expression in LUAD and its prognostic role in LUAD. The TNS4 is more expressed in tumor tissue than normal tissue by unpaired (a) or paired (b) comparison. LUAD with TNS4 over-expressed has poorer OS (c) and PFS (d). TNS4 expression has a positive correlation with poor overall survival (OS) by both univariate (e) and multivariate analysis (f). PFS = progression-free survival.
Figure 2. The relationship between TNS4 expression and clinical characteristics including age (a), gender (b), smoking history (c), stage (d), tumor size (e), and lymph nodes involvement (f).

Table 2  
TNS4 expression associated with clinical pathological characteristics (logistic regression).

| Clinical characteristics                  | Total number | Odds ratio in TNS4 expression (95% CI) | p value |
|-------------------------------------------|--------------|----------------------------------------|---------|
| Age (young vs old)                        | 490 (157 vs 333) | 1.06 (0.72–1.55)                       | .771    |
| Gender (female vs male)                   | 500 (270 vs 230) | 1.00 (0.70–1.42)                       | 1       |
| Smoking (nonsmoker vs smoker)             | 486 (71 vs 415) | 0.97 (0.58–1.60)                       | .898    |
| Stage I + II vs III + IV                  | 492 (387 vs 105) | 1.67 (1.08–2.61)                       | .022    |
| T factor (T1 vs T2 + T3 + T4)             | 497 (167 vs 330) | 1.56 (1.08–2.28)                       | .02     |
| Lymph nodes (negative vs positive)        | 489 (324 vs 165) | 1.78 (1.22–2.61)                       | .003    |
with the LUAD stage (Fig. 2d, \( P < .05 \)), with supporting evidence, such as the T factor (Fig. 2e, \( P < .05 \)) and lymph node status (Fig. 2f, \( P < .05 \)). Logistic regression analysis indicated that patients with high TNS4 expression had poor prognostic clinicopathologic characteristics compared to those with low TNS4 expression. Higher expression of TNS4 was significantly associated with the LUAD status, such as the disease stage (odds ratio [OR] = 1.67 and 95% CI 1.08–2.61, \( P < .05 \)), T factor (OR = 1.56 and 95% CI 1.08–2.28, \( P < .05 \)), and lymph node status (OR = 1.78 and 95% CI 1.22–2.61, \( P < .05 \)) (Table 2).

### 3.3. Meta-analysis for the predictive value of TNS4 expression in LUAD

Data obtained from six different datasets were included in our meta-analysis because of the lack of reports on the association between TNS4 expression and OS among LUAD patients. In the meta-analysis to determine the association between high TNS4 expression and OS in 1445 LUAD cases, the pooled HR was 1.24 and the 95%CI was 1.18 to 1.31. Furthermore, the heterogeneity among the four datasets was not significant (I² = 36%, \( P = .17 \), Fig. 3). All of the results indicated that up-regulated expression of TNS4 might be considered an important predictor for the OS of LUAD patients.

### 3.4. Identification of TNS4-related signaling pathways

In this study, GO and KEGG analyses were used to identify the signaling pathways that are differentially activated between the LUAD patients with high and low TNS4 expression. GO analysis revealed that some biological processes, cellular components, and molecular functions of the cytoskeleton and extracellular matrix (ECM) were enriched (Fig. 4a). GSEA analysis showed significant

| Study     | TE  | seTE  | Hazard Ratio | HR  | 95%–CI   | Weight |
|-----------|-----|-------|--------------|-----|----------|--------|
| GSE13213  | 0.10| 0.0830|              | 1.11| [0.94; 1.30]| 15.5%  |
| GSE26939  | 0.19| 0.0692|              | 1.21| [1.06; 1.39]| 18.3%  |
| GSE41271  | 0.21| 0.0948|              | 1.23| [1.02; 1.49]| 13.5%  |
| GSE42127  | 0.21| 0.1550|              | 1.23| [0.91; 1.67]| 7.0%   |
| GSE50081  | 0.68| 0.2061|              | 1.97| [1.31; 2.96]| 4.3%   |
| GSE72094  | 0.40| 0.0758|              | 1.49| [1.28; 1.72]| 16.9%  |
| TCGA      | 0.20| 0.0419|              | 1.23| [1.13; 1.33]| 24.5%  |

Figure 3. Meta-analysis of LUAD prognosis between high- and low- expression groups of TNS4.

Figure 4. Enrichment analysis of differentially expressed genes between high- and low- expression groups of TNS4. (a) GO analysis. (b) GSEA for KEGG analysis.
differences between high and low TNS4 expression (FDR < 0.05) in a dataset for the enrichment of molecular signatures (MSigDB Collection; c2.cp: KEGG, V7.1, symbols). In GSEA analysis, the most significantly enriched signaling pathways, based on the normalized enrichment score, were selected including focal adhesion, ECM receptor interaction, regulation of actin cytoskeleton, and glycosaminoglycan biosynthesis - chondroitin sulfate. The first four pathways in the results contained the top four gene sets. The focal adhesion genes were presented as an expression heatmap in Figure 4b–e. Correlation analysis showed that the genes that encode integrin α6β4 (ITGB4 and ITGA6) and its ligand, laminin-5 (LAMA3, LAMB3, and LAMC2), had a positive correlation with TNS4 (Fig. 5a–f).

4. Discussion and Conclusions

The family of tensin genes has four members, that is, tensin –1, –2, –3, and –4. TNS4, located in chromosome 17q12-q21, encodes a protein with 715 amino acids and has been identified as one of

Figure 5. The correlation between expression of TNS4 and other genes in focal adhesion pathway. (a–e) TNS4 has a positive relation with genes coding integrin α6β4 and its ligand, laminin-5. (f) The correlation between expression of TNS4 and genes in focal adhesion pathway. The genes coding integrin α6β4 and laminin-5 have been marked.
the tensin focal adhesion family members. It was recently reported that TNS4 expression is remarkably up-regulated in human cancers.[21–23] TNS4 mediates promoter activity in non-small cell lung cancer by inducing epithelial-mesenchymal transition and contributes to the development of resistance to tyrosine kinase inhibitors.[24] To our knowledge, the mechanism underlying the effect of TNS4 on the prognosis of LUAD has not yet been fully explored. Our bioinformatics study presented in this manuscript provides a more comprehensive prognostic analysis of LUAD. Further, the enrichment analysis results provide possible research directions for the study of the mechanism in the future.

To better understand the prognostic value of TNS4 expression in LUAD, we performed bioinformatics analysis in this study using high throughput RNA-sequencing data from the public TCGA database. The results showed a close correlation between the increased expression of TNS4 in LUAD and worse clinical pathologic characteristics, such as high clinical stage, increased tumor size, and lymph node involvement, as well as poor OS and PFS prognosis. Meta-analysis of 6 datasets also confirmed that higher TNS4 expression could be used as a biomarker for predicting poorer prognosis. Similarly, previous studies have shown that TNS4 plays a role in promoting tumor invasion and metastasis, implying a correlation between TNS4 expression and the disease stage.[22–26]

To investigate the potential mechanism underlying the role of TNS4 in the prognosis of LUAD, enrichment analysis was conducted using the GO and KEGG pathways. The results of the functional analysis showed that several pathways were enriched in the high-TNS4 population, including the cell junction, cytoskeleton, and ECM, which are involved in hemic desmosome assembly, ECM organization, and intermediate filament cytoskeleton in association with the development of many cancers.[28,29] GSEA also showed that several biological processes, such as glycosaminoglycan biosynthesis - chondroitin sulfate, regulation of the actin cytoskeleton, ECM receptor interactions, and focal adhesion were enriched in the high-TNS4 population. Unsurprisingly, the function of TNS4 is closely associated with the connection of the ECM to the cytoskeletal networks due to its role in focal adhesions.[30] TNS4 function is mainly mediated by integrin receptors and their associated protein complexes. In response to extracellular and intracellular stimuli, focal adhesions participate in the regulation of both extracellular and intracellular signaling pathways that regulate cellular events, such as gene expression, proliferation, differentiation, apoptosis, and cell attachment and migration.[31] In addition, TNS4 is known to interact with integrins to promote cell adhesion via stabilizing the β1 and β4 integrin.[32] The results also indicated that the expression of ITGA6 and ITGB4, the subunits of integrin α6β4, was positively correlated with the expression of TNS4. This may indicate a structural or functional correlation between TNS4 and integrin α6β4.

There are several limitations to this study. The present study is a retrospective study based on bioinformatics, and prospective and experimental studies are needed to validate the results obtained. The relation between TNS4 and integrin α6β4 is theoretical and should be interpreted with caution. LUAD is a multi-gene-driven disease. In this study, we only focused on TNS4 expression. However, we cannot conclude that TNS4 has a direct effect on LUAD prognosis or that it indirectly affects prognosis through other driving genes.

The overexpression of TNS4 may be one event that occurs during the period of lung cancer development, but the mechanism and relationship with lung cancer remain unclear. We believe that with further in-depth research on the TNS4 gene, the mechanism for its related genes and pathways in the occurrence and prognosis of lung cancer will be discovered.

In summary, we found that TNS4 is overexpressed in LUAD and can be used as a prognostic factor for the disease. The molecular mechanisms underlying the clinical value of TNS4 for predicting lung cancer prognosis may involve structural or functional correlations between TNS4 and integrin α6β4, which might be a topic for further investigation. Therefore, targeting TNS4 might be a potential therapeutic approach for human lung cancer.

Acknowledgements

We thank Medjaden Inc. for scientific editing of this manuscript.

Author contributions

Conceptualization: Feng Liu, Xinliang Gao, Wujun Xue.
Data curation: Feng Liu, Wei Liu.
Formal analysis: Feng Liu, Xinliang Gao, Wei Liu.
Investigation: Xinliang Gao.
Methodology: Xinliang Gao, Wujun Xue.
Project administration: Wujun Xue.
Software: Xinliang Gao.
Writing – original draft: Feng Liu, Wujun Xue.
Writing – review & editing: Feng Liu, Wei Liu, Wujun Xue.

References

[1] Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
[2] Houlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640–9.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
[4] Cheng TY, Cramb SM, Baade PD, et al. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11:1653–71.
[5] Lo S. Tensins. Curr Biol. 2017;27:R331–2.
[6] Liao YC, Lo SH. Tensins - emerging insights into their domain functions, biological roles and disease relevance. J Cell Sci. 2021;134:jcs254029.
[7] Kim S, Kim N, Kang K, et al. Whole transcriptome analysis identifies TNS4 as a key effector of cетuximab and a regulator of the oncogenic activity of KRAS mutant colorectal cancer cells. Cells. 2019;8:878.
[8] Aratani K, Komatsu S, Ichikawa D, et al. Correction: overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction. Oncotarget. 2019;10:5726.
[9] Sawazaki S, Oshima T, Sakamaki K, et al. Clinical significance of tensin 4 gene expression in patients with gastric cancer. In Vivo. 2017;31:1065–71.
[10] Chan LK, Chiu YT, Sze KM, et al. Tensin4 is up-regulated by EGFR-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. Oncotarget. 2015;6:20964–76.
[11] Spoestroom C, Khrsravi S, Zhang G, et al. C-terminal tensin-like protein is a novel prognostic marker for primary melanoma patients. PLoS One. 2013;8:e80492.
[12] Al-Ghamdi S, Cachat J, Albasri A, et al. C-terminal tensin-like gene functions as an oncogene and promotes cell motility in pancreatic cancer. Pancreas. 2013;42:135–40.
[13] Albasri A, Aleshkandarany M, Benhasouna A, et al. CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis. Breast Cancer Res Treat. 2011;126:47–54.
[14] Sasaki H, Yukiue H, Kobayashi Y, et al. Tensin4 mRNA expression is correlated with tumor progression in thymoma. Tumour Biol. 2013;34:271–7.
[15] Lo SH, Lo TB. Cten, a COOH-terminal tensin-like protein with functional restricted expression, is down-regulated in prostate cancer. Cancer Res. 2002;62:4217–21.
[16] Sasaki H, Moriyama S, Mizuno K, et al. Cten mRNA expression was correlated with tumor progression in lung cancers. Lung Cancer. 2003;40:151–5.
[17] Lu X, Gao J, Zhang Y, et al. CTEN induces epithelial-mesenchymal transition (EMT) and metastasis in non small cell lung cancer cells. PLoS One. 2018;13:e0198823.
[18] Muharram G, Sahpal P, Korpela T, et al. Tensin-4–dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Dev Cell. 2014;29:421–36.
[19] Zhang Y, Zhang X, Lv X, et al. Development and validation of a seven-gene signature for predicting the prognosis of lung adenocarcinoma. Biomed Res Int. 2020;2020:1836542.

[20] Misono S, Seki N, Mizuno K, et al. Molecular pathogenesis of gene regulation by the miR-150 duplex: miR-150-3p regulates TNS4 in lung adenocarcinoma. Cancers (Basel). 2019;11:601.

[21] Shi ZZ, Wang WJ, Chen YX, et al. The miR-1224-5p/TNS4/EGFR axis inhibits tumour progression in oesophageal squamous cell carcinoma. Cell Death Dis. 2020;11:597.

[22] Raposo TP, Alfahed A, Nateri AS, et al. Tensin4 (TNS4) is upregulated by Wnt signalling in adenomas in multiple intestinal neoplasia (Min) mice. Int J Exp Pathol. 2020;101:80–6.

[23] Asiri A, Toss MS, Raposo TP, et al. Cten promotes Epithelial-Mesenchymal Transition (EMT) in colorectal cancer through stabilisation of Src. Pathol Int. 2019;69:381–91.

[24] Lu X, Zhang Y, Pan Y, et al. Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer. Oncol Lett. 2021;12:2963.

[25] Fleming JC, Woo J, Moutasim K, et al. CTEN induces tumour cell invasion and survival and is prognostic in radiotherapy-treated head and neck cancer. Cancers (Basel). 2020;12:2963.

[26] Chang CC, Liu YC, Lin CH, et al. Histone acetyltransferase p300 mediates the upregulation of CTEN induced by the activation of EGFR signaling in cancer cells. Biochem Biophys Res Commun. 2021;534:53–8.

[27] Raposo TP, Susanti S, Ilyas M. Investigating TNS4 in the colorectal tumor microenvironment using 3D spheroid models of invasion. Adv Biosyst. 2020;4:e2000031.

[28] De Arcangelis A, Hamade H, Alpy F, et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut. 2017;66:1748–60.

[29] Liu CC, Lin SP, Hsu HS, et al. Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells. Nat Commun. 2016;7:11798.

[30] Legate KR, Fässler R. Mechanisms that regulate adaptor binding to beta-integrin cytoplasmic tails. J Cell Sci. 2009;122(Pt 2):187–98.

[31] Winograd-Katz SE, Fässler R, Geiger B, et al. The integrin adhesome: from genes and proteins to human disease. Nat Rev Mol Cell Biol. 2014;15:273–88.

[32] Seo EY, Jin SP, Kim YK, et al. Integrin-β4-TNS4-focal adhesion kinase signaling mediates keratinocyte proliferation in human skin. J Invest Dermatol. 2017;137:763–6.